Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control

被引：1

作者：

Blauvelt, Andrew ^{[1
]}

Langley, Richard G. ^{[2
]}

Peris, Ketty ^{[3
]}

Silvestre, Juan Francisco ^{[4
]}

Katoh, Norito ^{[5
]}

Tauber, Marie ^{[6
,7
]}

Pinter, Andreas ^{[8
]}

Ameen, Mahreen ^{[9
]}

Gooderham, Melinda ^{[10
,11
]}

Oland, Christian Bjerregard ^{[12
]}

Tindberg, Ann-Marie ^{[12
]}

Gjerum, Le ^{[12
]}

Reich, Kristian ^{[13
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] Dalhousie Univ, Div Clin Dermatol & Cutaneous Sci, Halifax, NS, Canada

[3] Univ Cattolica Sacro Cuore, Dermatol, Rome, Italy

[4] Hosp Gen Univ Dr Balmis, Dermatol Dept, ISABIAL, Alicante, Spain

[5] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kyoto, Japan

[6] Lyon Sud Hosp, Dept Allergol & Clin Immunol, Lyon, France

[7] INSERM, CIRI, U1111, Lyon, France

[8] Goethe Univ Frankfurt Main, Dept Dermatol Venereol & Allergol, Frankfurt, Germany

[9] Royal Free London Natl Hlth Serv Fdn Trust, London, England

[10] SKiN Ctr Dermatol, Peterborough, ON, Canada

[11] Queens Univ, Dept Dermatol, Kingston, ON, Canada

[12] LEO Pharma AS, Ballerup, Denmark

[13] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Translat Res Inflammatory Skin Dis, Hamburg, Germany

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 190卷

关键词：

long-term; efficacy; ECZTEND; tralokinumab; moderate-to-severe;

D O I：

10.1093/bjd/ljad498.050

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

551

引用

页码：II48 / II49

页数：2

共 50 条

[1] Dupilumab provides long-term efficacy over 2.5 years in adults with moderate-to-severe atopic dermatitis
Cork, Michael
Beck, Lisa
Bissonnette, Robert
Wollenberg, Andreas
Simpson, Eric
Praestgaard, Amy
Aamodt, Kimberly
Rossi, Ana
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 69 - 69
[2] Stability of long-term therapeutic responses to tralokinumab in adults with moderate-to-severe atopic dermatitis
Blauvelt, Andrew
Hong, H. Chih-ho
Peris, Ketty
Katoh, Norito
Tauber, Marie
Ameen, Mahreen
Gooderham, Melinda
Oland, Christian Bjerregard
Tindberg, Ann-Marie
Gjerum, Le
Reich, Kristian
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 30 - 31
[3] LONG-TERM EFFICACY OF TRALOKINUMAB IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Wollenberg, Andreas
Paller, Amy S.
Bewley, Anthony
Cork, Michael
Hong, Chih-Ho
Soong, Weily
Oland, Christian Bjerregard
Taveira, Christian Moreira
Gjerum, Le
Blauvelt, Andrew
ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 54 - 54
[4] Long-term improvements in disease severity, itch and quality of life after 3 years of tralokinumab treatment in adults with moderate-to-severe atopic dermatitis
Langley, Richard
Reich, Kristian
Simpson, Eric
Warren, Richard B.
Costanzo, Antonio
Saeki, Hidehisa
Fangel, Stine
Lassota, Nathan
Carlsson, Anna
Gooderham, Melinda
Lacour, Jean Philippe
Silvestre, Juan Francisco
Pinter, Andreas
Blauvelt, Andrew
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E123 - E125
[5] Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis
Chovatiya, Raj
Wollenberg, Andreas
Ribero, Simone
Saeki, Hidehisa
Oland, Christian B.
Steffensen, Louise A.
Tindberg, Ann-Marie
Thyssen, Jacob P.
Blauvelt, Andrew
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II49 - II50
[6] Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis
Chovatiya, Raj
Wollenberg, Andreas
Ribero, Simone
Saeki, Hidehisa
Oland, Christian B.
Steffensen, Louise A.
Tindberg, Ann-Marie
Thyssen, Jacob P.
Blauvelt, Andrew
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
[7] Dupilumab provides long-term efficacy over 2-5 years in adults with moderate-to-severe atopic dermatitis
Beck, L. A.
Bissonnette, R.
Wollenberg, A.
Simpson, E. L.
Thaci, D.
Praestgaard, A.
Aamodt, K.
Rossi, A. B.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E139 - E140
[8] Dupilumab provides long-term improvement in pruritus in children with severe atopic dermatitis and adolescents and adults with moderate-to-severe atopic dermatitis
Cork, Michael J.
Yosipovitch, Gil
Silverberg, Jonathan I.
Praestgaard, Amy
Zhang, Haixin
Wang, Zhixiao
Rossi, Ana B.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 79 - 79
[9] Long-term tralokinumab therapy in moderate to severe atopic dermatitis
Lorenz, Judith
AKTUELLE DERMATOLOGIE, 2023, 49 (03) : 91 - 91
[10] LONG-TERM SAFETY IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS TREATED WITH DUPILUMAB UP TO 4 YEARS
Blauvelt, A.
Eichenfield, L.
Sierka, D.
Chen, Z.
Khokhar, F.
Marco, A. Rodriguez
Shabbir, A.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S19 - S19

← 1 2 3 4 5 →